Form 4 for IMNM Immunome Inc.
Accepted 2026-07-07 17:42:16 ET · period of report 2026-07-02 · accession 0001997584-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-07 17:42 | 2026-07-02 | IMNM | Lechleider Robert | Chief Medical Off | M - OptEx | $8.73 | +55.0K | 70.8K | +348% | +$480.1K |
| DMT | 2026-07-07 17:42 | 2026-07-02 | IMNM | Lechleider Robert | Chief Medical Off | S - Sale+OE | $22.62 | -55.0K | 15.8K | -78% | -$1.24M |
| DT | 2026-07-07 17:42 | 2026-07-02 | IMNM | Lechleider Robert | Chief Medical Off | M - OptEx | $0.00 | -55.0K | 290.0K | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-02 | M | A | 55,000 | $8.73 | 70,805 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-02 | S | D | 22,714 | $21.95 | 48,091 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026. (F2) The weighted average sale price for the transaction report was $21.95, and the range of prices were between $21.26 and $22.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Common | Common Stock | 2026-07-02 | S | D | 16,214 | $22.76 | 31,877 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026. (F3) The weighted average sale price for the transaction report was $22.76, and the range of prices were between $22.26 and $23.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 4 | Common | Common Stock | 2026-07-02 | S | D | 16,072 | $23.44 | 15,805 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026. (F4) The weighted average sale price for the transaction report was $23.44, and the range of prices were between $23.26 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 5 | Derivative | Employee Stock Option (right to buy) | 2026-07-02 | M | D | 55,000 | $0.00 | 290,000 | D | $8.73 · — to 2033-10-26 | 55,000 Common Stock | (F5) 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years. |